Blood Proteins Patents (Class 435/69.6)
  • Patent number: 10973881
    Abstract: The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: April 13, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
  • Patent number: 10870695
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 22, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Patent number: 10844135
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: November 24, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Walter A. Blattler
  • Patent number: 10829565
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 10759861
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 1, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • Patent number: 10723801
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 28, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • Patent number: 10712345
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 10689630
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein an alpha-amylase and a thermostable hemicellulase is present and/or added during liquefaction. The invention also relates to compositions suitable for use in processes of the invention.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 23, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Zhengfang Kang, Christie Lynn Strahler, James Ron Huffman, Kristian Bertel Rømer M. Krogh
  • Patent number: 10640575
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 5, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10590457
    Abstract: The present invention relates to new methods and processes for culturing mammalian cells with the addition of phenolic antioxidants. Performance of the cell culturing methods and processes in their various aspects result in a higher viable cell density and higher protein titer.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 17, 2020
    Assignee: BRISTOL MYERS-SQUIBB COMPANY
    Inventors: Jun Tian, Jianlin Xu, Qin He
  • Patent number: 10557160
    Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 11, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 10472411
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: November 12, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10407484
    Abstract: The present disclosure relates to compositions and methods for modulating T-cell mediated immune response in a subject in need thereof. The method includes administering to the subject an effective amount of a CD112R protein, a fusion polypeptide, a complex including CD112R and a second protein, or an anti-CD112R antibody of the present disclosure.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 10, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Yuwen Zhu, Barish H. Edil, Richard D. Schulick, Alessandro Paniccia, Michelle Koenig, Alexander C. Schulick
  • Patent number: 10377812
    Abstract: The present invention describes a simple purification process for recombinant human serum albumin. The process results in highly purified protein with limited number of purification steps. The broth containing human albumin is clarified by centrifugation and microfiltration, diafiltered and captured by cation exchange chromatography by a process that allows 140-230 mg of albumin to be captured per ml of resin. Product related impurities are removed by hydrophobic interaction chromatography, optimized to allow 87-97% recovery in flow through mode. The final series of processes are so combined that there is easy transition from one step to the next with minimal interventions and adjustments. The entire process of purification is completed within two days from harvest to final product. Thus a cost-effective process with improved recovery of protein at each step is developed. The purified human serum albumin is analyzed for purity and shows physicochemical characteristics that are similar to standard albumin.
    Type: Grant
    Filed: January 1, 2016
    Date of Patent: August 13, 2019
    Assignee: NAVYA BIOLOGICALS PVT LTD
    Inventor: Rajyashri Ramakrishna Karur
  • Patent number: 10358479
    Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: July 23, 2019
    Assignee: ZYMEWORKS INC.
    Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
  • Patent number: 10336816
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: July 2, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10323287
    Abstract: This invention relates in part to plant breeding and herbicide tolerant plants. This invention includes a novel aad-1 transformation event in corn plants comprising a polynucleotide sequence, as described herein, inserted into a specific site within the genome of a corn cell. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. Additionally, the subject invention provides assays for detecting the presence of the subject event in a sample (of corn grain, for example). The assays can be based on the DNA sequence of the recombinant construct, inserted into the corn genome, and on the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are also provided.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Yunxing Cory Cui, Jill Bryan, Donald Maum, Greg Gilles, Terry Wright, Jennifer Hamilton, Nicole Arnold, Nathan VanOpdorp, Tina Kaiser, Ning Zhou
  • Patent number: 10280211
    Abstract: The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 7, 2019
    Assignee: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA
    Inventors: João Manuel Braz Goncalves, Frederico Nuno Castanheira Aires Da Silva
  • Patent number: 10267714
    Abstract: The present invention provides an aminoalcohol together with, as necessary, at least one selected from the group consisting of: at least one compound selected from the group consisting of urea and a urea derivative; a nonionic detergent; and sucrose to provide a biological material having an excellent light-transmitting property. The present invention provides a technique that allows a high-throughput observation of gene expression/localization or cell morphology in tissue at an whole-tissue level.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 23, 2019
    Assignee: RIKEN
    Inventors: Etsuo Susaki, Hiroki Ueda, Kazuki Tainaka
  • Patent number: 10247729
    Abstract: Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 2, 2019
    Assignee: MICROBPLEX, INC.
    Inventors: Frances Eun-Hyung Lee, John L. Daiss
  • Patent number: 10247745
    Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol that can enable full automation and reduced sample preparation time relative to current methods of glycoanalysis. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method without requiring time-consuming sample preparation steps such as centrifugation or vacuum-centrifugation.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 2, 2019
    Assignee: Beckman Coulter, Inc.
    Inventors: Andras Guttman, Clarence Lew, Marton Szigeti, Csaba Varadi
  • Patent number: 10221403
    Abstract: The present invention provides a method of preparing zearalenone hydrolase, including the step of culturing a yeast cell carrying a gene encoding a zearalenone hydrolase in a medium to express a protein of the zearalenone hydrolase, wherein the medium contains 20 to 25% molasses by weight. This method provides a new strategy to efficiently prepare zearalenone hydrolase at low expenses.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 5, 2019
    Assignee: LIFE RAINBOW BIOTECH CO., LTD.
    Inventors: Ching-Kuo Yang, Yu-Hsiang Yu, Ya-Chieh Huang, Rou-Wan Liao
  • Patent number: 10209164
    Abstract: The present invention provides an aminoalcohol together with, as necessary, at least one selected from the group consisting of: at least one compound selected from the group consisting of urea and a urea derivative; a nonionic detergent; and sucrose to provide a biological material having an excellent light-transmitting property. The present invention provides a technique that allows a high-throughput observation of gene expression/localization or cell morphology in tissue at an whole-tissue level.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: February 19, 2019
    Assignee: RIKEN
    Inventors: Etsuo Susaki, Hiroki Ueda, Kazuki Tainaka
  • Patent number: 10202443
    Abstract: Provided herein are antigen-binding constructs such as antibodies that bind to the RRM-1 domain of TDP-43. The antigen-binding constructs are capable of blocking the interaction of TDP-43 with NF-?B in cells. Also provided herein are method of using the antigen-binding constructs in the treatment of diseases associated with TPD-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), frontotemperal lobar degeneration (FTLD), Lewy body disease and motor neuron disease.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: February 12, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jean-Pierre Julien, Claude Gravel, Silvia Pozzi
  • Patent number: 10138294
    Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 27, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Gary Lesnicki, Patricia Dianne McNeill, Franz Hartner, Mark Young
  • Patent number: 10106610
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 23, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 10081675
    Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 25, 2018
    Assignee: MORPHOSYS AG
    Inventors: Francis Dodeller, Robert Rauchenberger
  • Patent number: 10023656
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10011856
    Abstract: The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Meixia Zhou, Bradley Richard Snedecor, Chi Kin Domingos Ng, Amy Shen
  • Patent number: 10011858
    Abstract: In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: July 3, 2018
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda
  • Patent number: 9988427
    Abstract: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 5, 2018
    Assignee: CHARITE UNIVERSITAETSMEDIZEN-BERLIN
    Inventors: Andreas Meisel, Josef Priller, Christel Bonnas, Ulrich Dirnagl
  • Patent number: 9982033
    Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 29, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
  • Patent number: 9982226
    Abstract: The present invention relates to discontinuous fed batch cell culturing of mammalian cells (more specific CHO cells) with the use of alternating bioreactors in combination with discontinuous separation of biomass from biological substance (more specific monoclonal antibodies) and waste components.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 29, 2018
    Assignee: BIOSANA PTY LTD
    Inventor: Jacob Arthur Tijsterman
  • Patent number: 9969797
    Abstract: Disclosed are antibodies (immunoglobulins) and fragments thereof that hydrolyze or bind polypeptide antigens belonging to Staphyloccus aureus, hepatitis C virus, human immunodeficiency virus and Alzheimer's disease. Also disclosed are novel methods to improve the antigen reactivity of the immunoglobulins and to treat a pathophysiological condition using the immunoglobulins as therapeutics.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: May 15, 2018
    Assignee: Covalent Bioscience Incorporated
    Inventors: Sudhir Paul, Stephanie Planque, Yasuhiro Nishiyama, Eric L. Brown, Keri C. Smith, Hiroaki Taguchi
  • Patent number: 9963511
    Abstract: Herein is reported an expression vector comprising—an antibody light chain expression cassette, —an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5? to 3? sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 8, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Peter Michael Huelsmann, Hendrik Knoetgen
  • Patent number: 9964548
    Abstract: Compositions and methods are provided for efficiently preparing a completely deglycosylated antibody where efficiency is measured in relative amounts of reagents in soluble or lyophilized form, and time and temperature of the reaction. Compositions and methods are also provided for separating substantially all N-linked glycans from a glycosylated antibody and for preserving functionality of the antibody. The methods are compatible with glycan labeling and protease digestion without the need for prior purification steps.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 8, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Paula Magnelli, Ellen Guthrie, Christopher H. Taron, Ming-Qun Xu, John Buswell
  • Patent number: 9957328
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 1, 2018
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9932412
    Abstract: A bispecific antigen binding protein complex comprising a first polypeptide comprising a first antigen binding site at an N terminus; a second polypeptide comprising a second antigen binding site at an N terminus; and a linker connecting the first polypeptide and the second polypeptide; wherein the linker comprises a tag at one terminus thereof, and wherein the tag is connected to a C-terminus of the first polypeptide or to an N-terminus of the second polypeptide, and comprises a cleavable amino acid sequence; as well as related compositions and methods.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: April 3, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Min-kyung Kim, JungWook Lee, SuJeong Hwang, Jaeil Lee
  • Patent number: 9920103
    Abstract: The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: March 20, 2018
    Assignees: BIOPROTEIN TECHNOLOGIES SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Pierre-Jean Ripoll, Laurent Lagrost
  • Patent number: 9849162
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: December 26, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9828429
    Abstract: Provided are methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). Also provided are methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies with a modified isoelectric point. Antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions are also disclosed.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 28, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
  • Patent number: 9828619
    Abstract: In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 28, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda
  • Patent number: 9822388
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 21, 2017
    Assignee: Amgen Inc.
    Inventors: Jian Wu, Sean Davern, Simina Crina Petrovan, Michael Charles Brandenstein, Katherine Rose Lindahl, Shawn Erik Lillie
  • Patent number: 9744217
    Abstract: The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. in one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 29, 2017
    Assignee: Nipro Corporation
    Inventors: Masaki Otagiri, Toru Maruyama, Yu Ishima, Ai Minomo
  • Patent number: 9676870
    Abstract: The technology described herein is directed to methods of treating cardiovascular and metabolic disorders.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: June 13, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Guo-Ping Shi
  • Patent number: 9670284
    Abstract: The present invention relates to methods of using VEGFR1 antibodies for the treatment of chronic kidney disease.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 6, 2017
    Assignee: Eli Lilly and Company
    Inventors: Zhonghua Qi, Matthew Douglas Breyer, Ling Liu
  • Patent number: 9663575
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 30, 2017
    Assignee: InhibRx, LP
    Inventors: Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Peter L. Nguy
  • Patent number: 9663572
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: May 30, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 9657321
    Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: May 23, 2017
    Assignee: Utah State University
    Inventors: Jon Y. Takemoto, Dong Chen
  • Patent number: 9605060
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 28, 2017
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventors: Roger Walker, Benedicte Jardin